Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer.

abstract：:Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic...

journal_title：Cancer chemotherapy and pharmacology

authors： Saban N,Bujak M

更新日期：2009-07-01 00:00:00

abstract：PURPOSE:The purpose of this investigation was to evaluate the effectiveness of oral 5-(phenylthio)acyclouridine (PTAU) in reducing 5-fluorouracil (FUra) host-toxicity and enhancing its chemotherapeutic efficacy against human colon tumors. PTAU is a potent and specific inhibitor of uridine phosphorylase (UrdPase, EC 2.4...

journal_title：Cancer chemotherapy and pharmacology

authors： Al Safarjalani ON,Rais R,Shi J,Schinazi RF,Naguib FN,el Kouni MH

更新日期：2006-11-01 00:00:00

abstract：:The interaction between cisplatin (cDDP) and tamoxifen (TAM) was evaluated in the human head and neck squamous-carcinoma cell lines UM-SCC-10B and UM-SCC-5. Synergy between cDDP and TAM was demonstrated in the UM-SCC-10B cell line. Concordant with the synergistic effect between cDDP and TAM, the rate of development of...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakata B,Albright KD,Barton RM,Howell SB,Los G

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib pharmacokinetics. METHODS:Plasma samples (N = 4886) were collected from 487 patients with various solid tumors (mainly melanoma) in three clinical studies (MEK4592g, NO25395, GO28141). Cobimetinib ...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Jin JY,Marchand M,Eppler S,Choong N,Hack SP,Tikoo N,Bruno R,Dresser M,Musib L,Budha NR

更新日期：2015-11-01 00:00:00

abstract：:Resistance to the clinically used platinum-based drugs cisplatin and carboplatin represents a major limitation to their clinical effectiveness. Using cisplatin-sensitive and -resistant human ovarian carcinoma cell lines previously characterized in terms of their major underlying mechanisms of resistance, we attempted ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sharp SY,Mistry P,Valenti MR,Bryant AP,Kelland LR

更新日期：1994-01-01 00:00:00

abstract：:A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively. The dose-limiting toxicity was c...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters WP,Stuart A,Klotman M,Gilbert C,Jones RB,Shpall EJ,Gockerman J,Bast RC Jr,Moore JO

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:The antifolate pralatrexate (10-propargyl-10-deazaaminopterin, PDX) demonstrates greater in vitro and in vivo antitumor efficacy than methotrexate. Preclinical models indicated that the efficacy of pralatrexate may be enhanced by coadministration with probenecid. The aim of this phase I study was to determine t...

journal_title：Cancer chemotherapy and pharmacology

authors： Fury MG,Krug LM,Azzoli CG,Sharma S,Kemeny N,Wu N,Kris MG,Rizvi NA

更新日期：2006-05-01 00:00:00

abstract：:To obtain a clearer definition of the relationship between the structure of BCNU and CCNU and their antitumor activity, we determined the uptake, distribution, and tissue/plasma partition ratios of both compounds in normal organs and intracerebral (ic) 9L tumors in rats. Greater uptake, distribution, and tissue/plasma...

journal_title：Cancer chemotherapy and pharmacology

authors： Levin VA,Kabra PA,Freeman-Dove MA

更新日期：1978-01-01 00:00:00

abstract：:New active drugs are needed for the treatment of primary brain tumors in both children and adults. S16020 is a cytotoxic olivacine derivative that inhibits topoisomerase II. The aim of the study was to determine its antitumor activity in athymic mice bearing subcutaneous medulloblastoma (IGRM33, 34, 57) and glioblasto...

journal_title：Cancer chemotherapy and pharmacology

authors： Vassal G,Merlin JL,Terrier-Lacombe MJ,Grill J,Parker F,Sainte-Rose C,Aubert G,Morizet J,Sévenet N,Poullain MG,Lucas C,Kalifa C

更新日期：2003-05-01 00:00:00

abstract：:The pharmacokinetics of soluble oral prednisolone were studied during induction therapy in six children with acute lymphoblastic leukaemia. There was a three- to four-fold variation in the pharmacokinetics of total and free prednisolone. For total prednisolone, the mean elimination half-life was relatively short (1.37...

journal_title：Cancer chemotherapy and pharmacology

authors： Choonara I,Wheeldon J,Rayner P,Blackburn M,Lewis I

更新日期：1989-01-01 00:00:00

abstract：:The antimetabolite 1-beta-D-arabinofuranosyl-cytosine (ara-C) has proven to be one of the most effective agents available for the treatment of acute leukemia. While ara-C has been implicated as a potent inhibitor of mammalian cell DNA replication, the specific mechanism by which ara-C kills cells is not known. In this...

journal_title：Cancer chemotherapy and pharmacology

authors： Wills P,Hickey R,Ross D,Cuddy D,Malkas L

更新日期：1996-01-01 00:00:00

abstract：:We have developed and validated a selective analytical procedure, based on ion-exchange normal-phase liquid chromatography with fluorescence detection and liquid-liquid extraction, for the analysis of vinblastine (VBL) in biological matrices. The assay is suitable for the determination of the parent compound and its m...

journal_title：Cancer chemotherapy and pharmacology

authors： van Tellingen O,Beijnen JH,Nooijen WJ,Bult A

更新日期：1993-01-01 00:00:00

abstract：:Modulators of protein kinase C (PKC) were used to investigate the role of this enzyme during Adriamycin-induced erythroid differentiation of K562 cells. Adriamycin (0.1 microM) induced erythroid differentiation in 60% +/- 10% of K562 cells. Phorbol myristate-12-acetate, an activator of protein kinase C, was strongly a...

journal_title：Cancer chemotherapy and pharmacology

authors： Hoffman R,Newlands ES

更新日期：1991-01-01 00:00:00

abstract：:Activation of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells leads to T cell exhaustion and ultimately facilitates tumor progression. Recent success of using immune cell checkpoint inhibitors offers a great promise to treat various cancers, including bladder cancer. However, the exp...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang W,Shi L,Zhao Z,Du P,Ye X,Li D,Cai Z,Han J,Cai J

更新日期：2019-05-01 00:00:00

abstract：:Thirty-eight patients with small cell carcinoma of the bronchus resistant to initial chemotherapy with cyclophosphamide methotrexate and CCNU, were treated with VP16-213 alone in a dose of 120 mg/m2 i.v. on days 1, 3, and 5 every 3 weeks. Twelve patients died before three courses of treatment. In 26 patients who recei...

journal_title：Cancer chemotherapy and pharmacology

authors： Harper PG,Dally MB,Geddes DM,Spiro SG,Smyth JF,Souhami RL

更新日期：1982-01-01 00:00:00

abstract：BACKGROUND:As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-D-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. M...

journal_title：Cancer chemotherapy and pharmacology

authors： Philips KB,Kurtoglu M,Leung HJ,Liu H,Gao N,Lehrman MA,Murray TG,Lampidis TJ

更新日期：2014-02-01 00:00:00

abstract：PURPOSE:Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as...

journal_title：Cancer chemotherapy and pharmacology

authors： Amato R,Stepankiw M,Gonzales P

更新日期：2013-06-01 00:00:00

abstract：PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

journal_title：Cancer chemotherapy and pharmacology

authors： Waud WR,Gilbert KS,Secrist JA 3rd

更新日期：2011-08-01 00:00:00

abstract：:The value of estrogen receptor (ER) status in the prediction of tumor response to combination chemotherapy was retrospectively analyzed in breast cancer patients selected for prospective controlled trials of chemotherapy (85 with advanced disease and 256 with operable tumors). All patients were previously untreated wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Bonadonna G,Valagussa P,Tancini G,Di Fronzo G

更新日期：1980-01-01 00:00:00

abstract：:A 62-year-old patient on long-term haemodialysis who developed an inoperable T2N3Mo squamous-cell carcinoma of the larynx was treated with weekly low-dose methotrexate (MTX) after failing to respond to radiotherapy. The patient was initially given one dose of 10 mg MTX (6 mg/m2) as a 1-h infusion, then he received thr...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomson AH,Daly M,Knepil J,Harden P,Symonds P

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:To characterize and compare pharmacokinetic parameters in children and adults treated with temozolomide (TMZ) administered for 5 days in three doses daily, and to evaluate the possible relationship between AUC values and hematologic toxicity. METHODS:TMZ pharmacokinetic parameters were characterized in pediatr...

journal_title：Cancer chemotherapy and pharmacology

authors： Riccardi A,Mazzarella G,Cefalo G,Garrè ML,Massimino M,Barone C,Sandri A,Ridola V,Ruggiero A,Mastrangelo S,Lazzareschi I,Caldarelli M,Maira G,Madon E,Riccardi R

更新日期：2003-12-01 00:00:00

abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

journal_title：Cancer chemotherapy and pharmacology

authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

更新日期：2017-12-01 00:00:00

abstract：PURPOSE:The artemisinin class of anti-malarial drugs has shown significant anti-cancer activity in pre-clinical models. Proposed anti-cancer mechanisms include DNA damage, inhibition of angiogenesis, TRAIL-mediated apoptosis, and inhibition of signaling pathways. We performed a phase I study to determine the maximum to...

journal_title：Cancer chemotherapy and pharmacology

authors： Deeken JF,Wang H,Hartley M,Cheema AK,Smaglo B,Hwang JJ,He AR,Weiner LM,Marshall JL,Giaccone G,Liu S,Luecht J,Spiegel JY,Pishvaian MJ

更新日期：2018-03-01 00:00:00

abstract：PURPOSE:Carboplatin is frequently dosed to achieve a desired area under the plasma concentration-time curve (AUC) by using the Calvert or Chatelut equations to estimate carboplatin clearance. Accurate determination of glomerular filtration rate (GFR) is necessary to correctly calculate carboplatin clearance using the C...

journal_title：Cancer chemotherapy and pharmacology

authors： Donahue A,McCune JS,Faucette S,Gillenwater HH,Kowalski RJ,Socinski MA,Lindley C

更新日期：2001-05-01 00:00:00

abstract：:The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28-72 mg/m2 DOX (nine courses). Plasma and parotid saliva were collected over a 48-h period, and DOX and DOXol were quantified by high-performance liquid chromatography...

journal_title：Cancer chemotherapy and pharmacology

authors： Bressolle F,Jacquet JM,Galtier M,Jourdan J,Donadio D,Rossi JF

更新日期：1992-01-01 00:00:00

abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...

journal_title：Cancer chemotherapy and pharmacology

authors： Chatelut E,Chevreau C,Brunner V,Martinez M,Houin G,Bugat R,Canal P

更新日期：1995-01-01 00:00:00

abstract：:Mercaptopurine (6MP) has been the standard drug for maintenance therapy of acute lymphoblastic leukemia. In a multicenter study we investigated whether thioguanine (6TG), which is converted more directly to the cytotoxic thioguanine nucleotides (TGN), offers a therapeutic advantage over 6MP. In this study (COALL-92), ...

journal_title：Cancer chemotherapy and pharmacology

authors： Erb N,Harms DO,Janka-Schaub G

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:This phase I study was undertaken to evaluate the safety and tolerability of prolonged infusional etoposide, and to evaluate its pharmacokinetic/pharmacodynamic profile in patients with advanced cancer. METHODS:A group of 17 patients received a 7-day infusion of etoposide (schedule A) every 21 days at doses fr...

journal_title：Cancer chemotherapy and pharmacology

authors： Robert F,Chen S,Miller AA,Lee BC,Molthrop DC,Wheeler RH

更新日期：1996-01-01 00:00:00

abstract：:To evaluate toxicity and efficacy of chemotherapy in elderly patients (> or = 65 years of age) with advanced colorectal cancer, data from two consecutive trials conducted between 1984 and 1995 at the National Institute for Cancer Research were analysed comparing the results of treatment in those 65 years of age or old...

journal_title：Cancer chemotherapy and pharmacology

authors： Chiara S,Nobile MT,Vincenti M,Lionetto R,Gozza A,Barzacchi MC,Sanguineti O,Repetto L,Rosso R

更新日期：1998-01-01 00:00:00

abstract：:We determined the kinetic parameters that describe the effect of 20 different modulators of the multidrug resistance pump on the reversal of cytotoxin accumulation in a resistant strain of P388 leukemia cells (P388/ADR), and on the reversal of cell killing for these cells. When measured by a direct comparison of the a...

journal_title：Cancer chemotherapy and pharmacology

authors： Lan LB,Ayesh S,Lyubimov E,Pashinsky I,Stein WD

更新日期：1996-01-01 00:00:00